Evolus, Inc. reported total revenue of $90.3 million for the fourth quarter of 2025, a 14% year‑over‑year increase from $79.0 million in Q4 2024. The full‑year 2025 revenue of $297.2 million grew 12% from $266.3 million in 2024, marking the company’s sixth consecutive year of double‑digit revenue growth.
The quarter’s operating results marked the first time Evolus posted a GAAP operating income of $4.2 million and a non‑GAAP operating income of $7.1 million. The company’s net income for Q4 2025 was $4.2 million on a GAAP basis, a turnaround from the $2.3 million GAAP loss from operations reported in Q4 2024. The non‑GAAP net income of $7.1 million reflects the company’s ability to generate positive earnings once one‑time and non‑recurring items are excluded.
Evolus confirmed its 2026 revenue guidance of $327 million to $337 million, unchanged from the prior guidance. Management emphasized that the guidance reflects confidence in continued demand for its core neurotoxin product Jeuveau and the recent launch of its Evolysse hyaluronic‑acid filler line, while noting that operating leverage is improving as cost‑control measures take effect.
Revenue growth was driven by a 15% increase in Jeuveau sales, which accounted for roughly 70% of total revenue, and a 25% rise in Evolysse sales, which now represents about 20% of revenue. International revenue grew to $23.8 million, up 10% from the previous year, reflecting stronger demand in key overseas markets. The company’s gross profit margin remained steady at 66.5%, supported by a favorable product mix and efficient manufacturing operations.
In a statement, President and CEO David Moatazedi said, “We achieved profitability in the fourth quarter, reflecting the benefits of decisive expense actions we implemented in the second quarter, proactively rebasing our expense structure to align with current market conditions while preserving our growth trajectory.” CFO Tatjana Mitchell added, “The organization responded with clear prioritization, thoughtful cost management and a focused allocation of resources toward the highest return initiatives. That discipline allowed us to deliver fourth‑quarter profitability and positions us well for sustainable annual profitability beginning in 2026.”
Market participants noted the slight revenue miss of $0.3 million below analyst consensus of $90.75 million to $91.5 million, but the non‑GAAP EPS beat of $0.06 versus the consensus of $0.051 was viewed positively. The company’s guidance and demonstrated profitability contributed to a tempered market reaction, with analysts acknowledging the company’s resilience amid a declining procedural environment and competitive pressures from new neurotoxin launches.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.